Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02685267 · ClinicalTrials.gov registry record · Phase 2
Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer
A Phase 2 study, sponsored by Prostate Cancer Clinical Trials Consortium.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02685267: Clinical Trial Phase 2 study, sponsored by Prostate Cancer Clinical Trials Consortium.
NCT02685267 is a Phase 2 study that was terminated before completion, run by Prostate Cancer Clinical Trials Consortium. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02685267, a Phase 2 study, was terminated before completion, sponsored by Prostate Cancer Clinical Trials Consortium.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a prospective randomized phase II clinical trial where patients who are receiving enzalutamide in the pre-chemotherapy space are randomized upon objective progression (radiographic and/or clinical per PCWG2 criteria) to docetaxel/prednisone alone or the same combination plus enzalutamide. The primary aim is to evaluate whether continuing enzalutamide in combination with docetaxel in patients who failed or progressed while on enzalutamide would increase progression-free survival (PFS) by 4 months. The secondary end points are PSA responses, percent of patients alive at 1 and 2 years, decline in circulating tumor cells (CTCs), and quality of life (QOL) using validated scales.
Interventions
- DRUG Docetaxel
- DRUG Prednisone
- DRUG Enzalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02685267
The ClinicalTrials.gov registry entry for NCT02685267 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prostate Cancer Clinical Trials Consortium, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT02685267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02685267 about?
NCT02685267 is a clinical study titled "Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer". This is a prospective randomized phase II clinical trial where patients who are receiving enzalutamide in the pre-chemotherapy space are randomized upon objective progression (radiographic and/or clinical per PCWG2 criteria) to docetaxel/prednisone alone or the same combination plus enzalutamide. T...
What is the current status of trial NCT02685267?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2016-02. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02685267?
The interventions under investigation include: Docetaxel (DRUG), Prednisone (DRUG), Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT02685267?
This trial is sponsored by Prostate Cancer Clinical Trials Consortium, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.